Bo Franzén

Bo Franzén

Karolinska Institutet

H-index: 36

Europe-Sweden

About Bo Franzén

Bo Franzén, With an exceptional h-index of 36 and a recent h-index of 13 (since 2020), a distinguished researcher at Karolinska Institutet, specializes in the field of cancer, diagnostics, biomarkers, therapy prediction.

His recent articles reflect a diverse array of research interests and contributions to the field:

Minimally invasive biopsy‐based diagnostics in support of precision cancer medicine

Multiplex protein analysis and ensemble machine learning methods of fine needle aspirates from prostate cancer patients reveal potential diagnostic signatures associated with …

Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients

Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome

P2. 13-03 Plasma Profiling Unveils Transcriptional Signatures Associated with Resistance to Osimertinib in Non-Small Cell Lung Cancer

Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial

Multiplex immune protein profiling of fine‐needle aspirates from patients with non‐small‐cell lung cancer reveals signatures associated with PD‐L1 expression and tumor stage

Bo Franzén Information

University

Position

Associate Professor

Citations(all)

3525

Citations(since 2020)

506

Cited By

3164

hIndex(all)

36

hIndex(since 2020)

13

i10Index(all)

55

i10Index(since 2020)

18

Email

University Profile Page

Karolinska Institutet

Google Scholar

View Google Scholar Profile

Bo Franzén Skills & Research Interests

cancer

diagnostics

biomarkers

therapy prediction

Top articles of Bo Franzén

Title

Journal

Author(s)

Publication Date

Minimally invasive biopsy‐based diagnostics in support of precision cancer medicine

Bo Franzén

Gert Auer

Rolf Lewensohn

2024/3/22

Multiplex protein analysis and ensemble machine learning methods of fine needle aspirates from prostate cancer patients reveal potential diagnostic signatures associated with …

Cytopathology

Pontus Röbeck

Bo Franzén

Rafaele Cantera‐Ahlman

Anca Dragomir

Gert Auer

...

2023/7

Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients

Translational Lung Cancer Research

Andrey Alexeyenko

Odd Terje Brustugun

Inger Johanne Zwicky Eide

Radosveta Gencheva

Zeinab Kosibaty

...

2022/10

Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome

Molecular Oncology

Kristina Viktorsson

Petra Hååg

Carl‐Henrik Shah

Bo Franzén

Vasiliki Arapi

...

2022/10

P2. 13-03 Plasma Profiling Unveils Transcriptional Signatures Associated with Resistance to Osimertinib in Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

A Alexeyenko

OT Brustugun

IJ Zwicky Eide

R Gencheva

Z Kosibaty

...

2022/9/1

Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial

Acta Oncologica

Ellen Backlund

Muyi Yang

Vitali Grozman

Giuseppe Masucci

Johan Falkenius

...

2022/7/3

Multiplex immune protein profiling of fine‐needle aspirates from patients with non‐small‐cell lung cancer reveals signatures associated with PD‐L1 expression and tumor stage

Molecular Oncology

Bo Franzén

Kristina Viktorsson

Caroline Kamali

Eva Darai‐Ramqvist

Vitali Grozman

...

2021/11

See List of Professors in Bo Franzén University(Karolinska Institutet)